Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Quality detection method of a compound Chinese medicine

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Aminoacyl tRNA synthetases for modulating inflammation

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Mobile image digital copyright secure processing system based on digital watermark technology

The invention relates to a digital copyright management safety processing system on a moving terminal. It demands the packing and undoing using digital watermark at the server end and customer end. Compared with existing displacement image digital copyright processing system, it has the following advantages: It can identify whether the user has the legitimate right. It can track the first right violator after the right violation. It has copyright ownership identification ability. It adds completeness check of the displacement image right to prevent the right information being changed in the Combined delivery method defined in OMA DRM 1.0. It intensifies the protective mechanism of the displacement image copyright. It lowered the complexity of the computing of the moving image embedded with watermark to resist the damage to the compressed code and with bigger effective loading water mark.

A detection method for externally applied medicine for hemorrhoids

The invention discloses a detection method for externally applied medicine for hemorrhoids. The externally applied medicine is composed of PIEN TZE HUANG, pearl powder, amber and borneol and prepared by grinding, pasting, heating, cooling, stirring and emulsion for the different ingredients. In the detection method of the invention the externally applied medicine is discriminated and content is determined; The detection method is specialized and stably controlled for quality.

Gynura formosana Kitam total flavonoids extract, preparation method thereof, and applications of gynura formosana Kitam total flavonoids extract in treating non-alcoholic fatty liver disease

The invention belongs to the field of drug or health care product, and more specifically relates to a gynura formosana Kitam. total flavonoids extract, a preparation method thereof, and applications of the gynura formosana Kitam. total flavonoids extract in treating non-alcoholic fatty liver disease. The gynura formosana Kitam. total flavonoids extract comprises, by weight, 80 to 85% of rutin. Itis shown by drug effect experiment results that the gynura formosana Kitam. total flavonoids extract possesses relatively excellent curative effect on non-alcoholic fatty liver disease, is capable ofimproving lipid disorders and fatty degeneration of mice with non-alcoholic fatty liver disease, and can be taken as a potential drug used for treating non-alcoholic fatty liver disease. According tothe preparation method, after extraction, a composite enzyme is composed of enzymes of specific composition and specific ratio, and is used for enzymatic hydrolysis; and in addition, macroporous resinextraction ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

AMINOACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Abstract Inflammatory and other cellular response-modulating compositions are provided comprising ) aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AND PREPARATION METHOD THEREOF

The present invention declares a pharmaceutical composition for treating diabetes, said pharmaceutical composition mainly comprises Feculae Bombycis and Radix Glycyrrhizae. The present invention declares also declares preparation method and quality control method of said pharmaceutical composition. Said pharmaceutical composition can reduce blood sugar as well as relieve intestinal tympanites.

AMINOACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-TRNA SYNTHETASE

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Organic light-emitting element and manufacturing method thereof

The present invention provides an organic light-emitting element and a manufacturing method thereof. The organic light-emitting element includes a gate electrode, a dielectric layer disposed on the gate electrode, an active layer disposed on the dielectric layer, the active layer having a source region located at an edge of the active layer, a drain region located at a center of the active layer, and a channel region between the source region and the drain region, an organic light-emitting layer disposed on the drain region, a drain electrode disposed above the organic light-emitting layer, and a source electrode disposed on the source region.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-TRNA SYNTHETASE

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED PROTEIN FRAGMENTS OF TRYPTOPHANYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Aminoacyl tRNA synthetases for modulating inflammation

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Laminated, compact and optimized energy-saving intensive flue-curing barn for flue-cured tobacco

The invention relates to a laminated, compact and optimized energy-saving bulk flue-curing barn for flue-cured tobacco, which is composed of a heating room, a fan and a hot-air channel. The energy-saving bulk flue-curing barn is characterized by being composed of 4-8 single bulk flue-curing rooms which are arranged side by side or horizontally and are respectively independent, wherein the inlet port of the hot-air channel of a first bulk flue-curing room is communicated with the high-temperature hot-air channel of the heating room; the outlet port of the hot-air channel of the first bulk flue-curing room is communicated with the inlet port of the hot-air channel of a second bulk intensive flue-curing room; and the outlet port of the hot-air channel of the last bulk flue-curing room (19) is communicated with the outside, the heating room or other flue-curing barns which require reversion after ceasing fire. The bulk flue-curing barn has various advantages, complies with the national conditions ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

COMPOSITIONS AND METHODS COMPRISING ASPARTYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES

Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

COMPOSITIONS AND METHODS COMPRISING ASPARTYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES

Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. 137-. (canceled)38. A pharmaceutical composition , comprising a physiologically-acceptable carrier and an aspartyl-tRNA synthetase (AspRS) polypeptide consisting of 50-200 amino acids in length that comprises (a) amino acid residues 1-154 , 1-171 , or 1-174 of SEQ ID NO: 1 , or (b) an active variant having at least 95% sequence identity to the polypeptide of (a) , wherein the AspRS polypeptide comprises an amphiphilic helix , and wherein the composition has an LPS-containing bacterial endotoxin level of less than about 12 EU/mg.39. The pharmaceutical composition of claim 38 , wherein the active variant has at least 98% identity to the polypeptide of (a).40. The pharmaceutical composition of claim 38 , wherein the AspRS polypeptide consists essentially of amino acid residues 1-154 claim 38 , 1-171 claim 38 , or 1-174 of SEQ ID NO:1.41. The pharmaceutical composition of claim 40 , wherein the AspRS polypeptide consists essentially of amino acid residues 1-154 of SEQ ID NO:1.421. The pharmaceutical composition of claim 38 , wherein the active variant comprises at least one substitution in the amphiphilic helix which modulates the ability of the variant to induce IL-10 cytokine release from PBMCs relative to an AspRS polypeptide of claim (a).43. The pharmaceutical composition of claim 42 , wherein the at least one point mutation is at position E12 claim 42 , E16 claim 42 , or D19.44. The pharmaceutical composition of claim 38 , wherein the AspRS polypeptide is modified by pegylation.45. The pharmaceutical composition of claim 38 , wherein the AspRS polypeptide is fused to a heterologous fusion partner.46. The pharmaceutical composition of claim 45 , wherein the heterologous fusion partner comprises an Fc fragment.47. The pharmaceutical composition of claim 38 , wherein the composition is ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AND PREPARATION METHOD THEREOF

A pharmaceutical composition for treating diabetes and preparation methods, quality control methods and uses thereof, said pharmaceutical composition is prepared by using silkworm shit and licorice as raw materials, it not only can reduce blood sugar, but also can improve flatulence.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED PROTEIN FRAGMENTS OF TRYPTOPHANYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Pharmaceutical composition capable of reducing weight and preparation method thereof

The invention provides a pharmaceutical composition capable of reducing weight, which comprises the following components by weight: 10-20 parts of konjak fine flour, 8-16 parts of red yeast rice, 2-12 parts of agaricus bisporus extract product, 1-6 parts of tea polyphenol and 1-6 parts of curcumin. The pharmaceutical composition can be prepared to clinically acceptable capsules, tablets, pills, a particulate agent, oral liquid, syrup, an electuary, medicinal liquor, a paste agent, powder, an injection or a beverage. The employed agaricus bisporus extract is chitin from agaricus bisporus, compared with chitin from shrimp and crab, chitin from agaricus bisporus is safer and anallergic, and the heavy metal and ash index are easier to be controlled.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-TRNA SYNTHETASE

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Pharmaceutical composition for treating diabetes and preparation method thereof

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

AMINOACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

OLED structure for improving color purity and manufacturing method thereof

The invention discloses an OLED structure for improving color purity. The OLED structure for improving color purity comprise a substrate, a metal anode layer, an organic light-emitting layer, a cathode layer, a color reflecting layer and a transparent anode layer, wherein the metal anode layer is manufactured on the substrate; the organic light-emitting layer is manufactured on the metal anode layer, and a first color light-emitting device, a second color light-emitting device and a third color light-emitting device are arranged in the organic light-emitting layer respectively; the cathode layer is manufactured on the organic light-emitting layer; the color reflecting layer is manufactured between the metal anode layer and the organic light-emitting layer, the color reflecting layer comprises a first color reflective device, a second color reflective device and a third color reflective device, and the first color reflective device, the second color reflective device and the third color ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Multi-Level Parallel Power Converters

Multi-level power converters are disclosed. In one embodiment, a multi-level power converter includes an input for receiving an input voltage and a converter output for providing a variable output voltage. The multi-level power converter includes a plurality of switching circuits. Each switching circuit is connected to the input in parallel with each other switching circuit. Each switching circuit includes an output. Each switching circuit is selectively operable to couple its output to the input voltage or a reference voltage. The multi-level power converter includes a parallel multi-winding autotransformer (PMA). The PMA includes a plurality of windings and a magnetic core having a plurality of magnetically connected columns. Each winding is positioned around a different one of the columns and has a beginning and an end. The output of each switching circuit is coupled to the beginning of a different winding. The end of each winding is connected to the converter output in parallel with each other winding. 1. A multi-level power converter comprising:an input for receiving an input voltage;a converter output for providing a variable output voltage;a plurality of switching circuits, each switching circuit connected to the input in parallel with each other switching circuit, each switching circuit including an output, each switching circuit selectively operable to couple its output to the input voltage or a reference voltage; anda parallel multi-winding autotransformer (PMA), the PMA including a plurality of windings and a magnetic core having a plurality of magnetically connected columns, each winding positioned around a different one of the columns, each winding having a beginning and an end, the output of each switching circuit coupled to the beginning of a different winding, the end of each winding connected to the converter output in parallel with each other winding.2. The multi-level power converter of wherein the plurality of windings are all wound in a same ...

Core and Coil Construction for Multi-Winding Magnetic Structures

Multi-winding magnetic structures and methods of making multi-winding magnetic structures are disclosed. In one embodiment, a multi-winding magnetic structure includes a core constructed of a magnetic material and a plurality of windings. The core includes a core top, a core bottom, and a plurality of columns. The core top has an exterior edge defining a shape of the core top. A central section of the core top has a substantially constant thickness that defines a thickness of the core top. The core bottom is beneath the core top and has an exterior edge defining a shape of the core bottom. A central section of the core bottom has a substantially constant thickness that defines a thickness of the core bottom. The thickness of one of the core bottom and the core top decreases from an edge of its central section to its exterior edge. The plurality of columns extends from the core bottom to the core top and the plurality of windings are wound around the columns. 119-. (canceled)20. A multi-winding magnetic structure comprising:a magnetic core, the core including a core top having an exterior edge, a central section of the core top having a substantially constant thickness and an edge;a core bottom beneath the core top, the core bottom having an exterior edge, a central section of the core bottom having a substantially constant thickness and an edge, the thickness of one of the core bottom and the core top decreasing from the edge of its central section to its exterior edge;at least three columns extending between the core bottom and the core top; andat least three windings, a different one of the at least three windings wound around each of the at least three columns.21. The multi-winding magnetic structure of wherein the thickness of the core bottom decreases from the edge of its central section to the exterior edge of the core bottom and the thickness of the core top decreases from the edge of its central section to the exterior edge of the core top.22. The multi- ...

Miniature surface mount device with large pin pads

One embodiment of the surface mount LED package includes a lead frame and a plastic casing at least partially encasing the lead frame. The lead frame includes a plurality of electrically conductive chip carriers. There is an LED disposed on each one of the plurality of electrically conductive chip carriers. A profile height of the surface mount LED package is less than about 1.0 mm.

WATERPROOF SURFACE MOUNT DEVICE PACKAGE AND METHOD

The present invention is directed to LED packages and methods utilizing waterproof and UV resistant packages with improved structural integrity. In some embodiments, the improved structural integrity is provided by various features in the lead frame that the casing material encompasses to improve the adhesion between the lead frame and the casing for a stronger, waterproof package. Moreover, in some embodiments the improved structural integrity and waterproofing is further provided by improved adhesion between the encapsulant and the casing. Some embodiments also provide for improved wire bonds, with the length, thickness, and loop height of the wire bonds controlled and optimized for improved adhesion between the wire bonds and the encapsulant as well as improved reliability. 1. An emitter package , comprising:a casing comprising a cavity extending into the interior of said casing from a top surface of said casing;an electrically conductive lead frame integral to said casing;a plurality of light emitting devices arranged on conductive carrier parts of said lead frame, said light emitting devices and portions of said lead frame exposed through said cavity; anda plurality of wire bonds electrically connecting each of said light emitting devices to conductive connection parts of said lead frame, wherein the length, thickness, and loop height of said wire bonds is controlled to improve reliability of said package; andwherein said emitter package is substantially UV resistant and waterproof.2. The emitter package of claim 1 , wherein said lead frame comprises features to enhance adhesion between said casing and said lead frame claim 1 , with the material of said casing encompassing each of said features.3. The emitter package of claim 2 , wherein said lead frame features comprise one or more of or any combination of the following: through-holes claim 2 , cuts claim 2 , bends claim 2 , indentations claim 2 , tabs claim 2 , steps claim 2 , or metal gaps between adjacent ...

Thermoplastic Polymer Blends Comprising Crosslinked Polar Olefin Polymers in a Thermoplastic Polyurethane Matrix

Polymer blends comprising a first phase comprising a thermoplastic polyurethane matrix and a second phase comprising a crosslinked polar olefin polymer are provided. The first phase is a continuous phase and the second phase can be co-continuous with the first phase, or dispersed as a non-continuous phase in the first phase. The first phase further comprises a metal hydroxide flame retardant and an organic flame retardant. The second phase further includes a metal hydroxide which is coupled to the olefin polymer via a silane coupling agent. 1. A polymer blend comprising:(a) a continuous phase comprising a thermoplastic polyurethane, a metal hydroxide and at least one organic flame retardant; and(b) a dispersed or co-continuous phase dispersed in the continuous phase or co-continuous with the continuous phase and comprising a crosslinked polar olefin polymer and the metal hydroxide, wherein the polar olefin polymer is coupled to the metal hydroxide via a silane coupling agent.2. The blend of claim 1 , in which the polar olefin polymer is an ethylene vinyl acetate polymer.3. The blend of claim 1 , in which the continuous phase further comprises an epoxidized novolac resin.4. The blend of claim 1 , in which the metal hydroxide is homogenously dispersed through the continuous phase and the dispersed or co-continuous phase.5. The blend of comprising 40 to 80 weight percent thermoplastic polyurethane claim 1 , based on the total weight of polymer components of the blend claim 1 , 20 to 60 weight percent polar olefin polymer claim 1 , based on the total weight of the polymer components of the blend claim 1 , and 40 to 60 weight percent metal hydroxide claim 1 , based on the total weight of the blend.6. The blend of claim 1 , in which the crosslinked polar olefin polymer is a peroxide crosslinked polar olefin polymer.7. An article comprising the blend of .8. A method of making a polymer blend claim 1 , the method comprising:(a) mixing a thermoplastic polyurethane polymer, a ...

Halogen-Free, Flame Retardant Compositions for Wire and Cable Applications

A halogen-free, flame retardant composition comprises thermoplastic polyurethane, olefin block copolymer, carbonyl-containing olefin polymer compatibilizer, and flame retardant package comprising bisphenol-A bis(diphenyl phosphate) and/or resorcinol bis(diphenyl phosphate), a nitrogen/phosphorus based, halogen-free flame retardant, and epoxidized novolac. The composition that will not only be processed easily to make a wire or cable sheath but also pass both the VW-1 flame retardancy test and the UL1581 heat deformation test at 150° C. exhibits good tensile and flexibility properties. 1. A composition comprising:A. Thermoplastic polyurethane (TPU),B. Olefin block copolymer (OBC),C. Carbonyl-containing olefin polymer compatibilizer, andD. Flame retardant package comprising (1) at least one of bisphenol-A bis(diphenyl phosphate) (BPADP) or resorcinol bis(diphenyl phosphate (RDP), (2) a nitrogen/phosphorus based, halogen-free flame retardant, and (3) epoxidized novolac.2. The composition of in which the TPU claim 1 , OBC and compatibilizer comprise a polymer matrix in which the flame retardant package is dispersed claim 1 , and the combination of OBC and carbonyl-containing polymer comprises less than 30 weight percent of the polymer matrix.3. The composition of in which the TPU is either polyester or polyether-based polyurethane claim 2 , the OBC is an ethylene multi-block copolymer claim 2 , and the carbonyl-containing olefin polymer is at least one of an MAH-g-olefin elastomer and an MAH-g-OBC.4. The composition of in which the BPADP/RDP component of the flame retardant package comprises 5 to 20 wt % of the composition claim 3 , the nitrogen/phosphorus claim 3 , halogen-free component of the flame retardant package comprises 30 to 60 wt % of the composition claim 3 , and the epoxidized novolac resin comprises 0.1 to 10 wt % of the composition.5. The composition of further comprising at least one of an antioxidant claim 1 , UV stabilizer claim 1 , light stabilizer ...

SEMICONDUCTOR DEVICE

Plural island-form emitter cells () having a p-base region () and an n emitter region () are provided, distanced from each other, on a main surface of an n layer (). A trench () deeper than the p-base region () is formed on either side of the emitter cell (). A first gate electrode () is embedded in the trench () across a first gate insulating film (). A second gate electrode () that electrically connects first gate electrodes () is provided, across a second gate insulating film (), on a surface of a region of the p-base region () sandwiched by the n emitter region (). A conductive region () that electrically connects second gate electrodes () is provided, across a third gate insulating film (), on a surface of the n layer (). A contact region () that is isolated from the second gate electrode (), and that short circuits the n emitter region () and p-base region (), is provided. 1. A semiconductor device , characterized by comprising:a first conductivity type semiconductor layer;a plurality of island-form cells provided distanced from each other on a first main surface of the first conductivity type semiconductor layer;a second conductivity type semiconductor region provided in the cell;a first conductivity type semiconductor region provided in the second conductivity type semiconductor region;a first insulating film provided inside a trench deeper than the second conductivity type semiconductor region formed on either side of the cell;a first electrode embedded in the trench across the first insulating film;a second insulating film provided on a surface of a region of the second conductivity type semiconductor region sandwiched by the first conductivity type semiconductor region;a second electrode, formed on the second insulating film, that electrically connects first electrodes;a third insulating film provided on a surface of the first conductivity type semiconductor layer;a conductive region, formed on the third insulating film, that electrically connects second ...

Halogen-Free, Flame Retardant Composition Comprising Crosslinked Silane-g-EVA

Halogen-free, flame retardant compositions comprising in weight percent based on the weight of the composition: A. 20 to 60% TPU/Si-g-EVA polymer blend in which the Si-g-EVA is crosslinked, B. 1 to 25% organic phosphate ester, C. 30 to 60% metal hydrate, and D. 0.1 to 10% epoxidized novolac. Optionally, the compositions further comprise in weight percent based on the weight of the composition, one or more of: E. 0.01 to 0.5% anti-dripping agent, F. 0.1 to 2% additive; and G. 0.1 to 5% filler. 1. A halogen-free , flame retardant composition comprising in weight percent based on the weight of the composition:A. 20 to 60% TPU/Si-g-EVA polymer blend in which the Si-g-EVA is crosslinked,B. 1 to 25% organic phosphate ester,C. 30 to 60% metal hydrate, andD. 0.1 to 10% epoxidized novolac.2. The composition of in which the polymer blend comprises 50 to 95 wt % TPU and 5 to 50 wt % Si-g-EVA claim 1 , based on the weight of TPU/Si-g-EVA polymer blend.3. The composition of in which the Si-g-EVA comprises a vinyl acetate content of 10-70 wt % based on the weight of the EVA copolymer.4. The composition of in which the Si-g-EVA comprises a silane content of 0.5-10 wt % based on the weight of the EVA copolymer.5. The composition of in which the organic phosphate ester is at least one of resorcinol bis(diphenyl phosphate) (RDP) and bisphenol-A bis(diphenyl phosphate) (BPADP) and is present in an amount of 5 to 20 wt %.6. The composition of in which the metal hydrate is at least one of aluminum trihydroxide (ATH) and magnesium hydroxide and is present in an amount of 35 to 55 wt %.7. The composition of further comprising at least one of an anti-dripping agent claim 6 , an antioxidant claim 6 , UV-stabilizer claim 6 , processing aid and filler.8. The composition of in which the TPU is at least one of polyether-based and polyester-based polyurethane and is present in an amount of 60 to 90 wt % claim 7 , based on the weight of TPU/Si-g-EVA polymer blend.9. An article comprising the ...

AMINO ACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions. 1114-. (canceled)115. A method for treating an inflammatory or autoimmune condition in a subject in need thereof , comprising; administering to the subject a pharmaceutical composition that comprises a pharmaceutically acceptable carrier and a histidyl-tRNA synthetase (HRS) polypeptide , where the HRS polypeptide comprises the amino acid sequence of SEQ ID NO:28 or a variant thereof that differs from SEQ ID NO:28 by 1-5 amino acids , and where the HRS polypeptide has an anti-inflammatory activity.116. The method of claim 115 , where the HRS polypeptide is about 509 amino acids in length.117. The method of claim 116 , where the HRS polypeptide consists essentially of the amino acid sequence of SEQ ID NO:28.118. The method of claim 115 , where the N- or C-terminal region of the variant is truncated by about 1 claim 115 , 2 claim 115 , 3 claim 115 , 4 claim 115 , or 5 amino acids.119. The method of claim 115 , where the variant is substituted by about 1 claim 115 , 2 claim 115 , 3 claim 115 , 4 claim 115 , or 5 conservative amino acid substitutions.120. The method of claim 115 , where the C-terminal region of the variant is truncated by 3 amino acids.121. The method of claim 115 , where the HRS polypeptide is modified by pegylation.122. The method of claim 115 , where the HRS polypeptide is a fusion protein that further comprises a heterologous fusion partner.123. The method of claim 122 , where the HRS polypeptide fusion protein comprises a linker.124. The method of claim 122 , where the HRS polypeptide fusion protein comprises a heterologous signal peptide.125. The method of claim 122 , where the heterologous ...

SEMICONDUCTOR DEVICE AND SEMICONDUCTOR DEVICE MANUFACTURING METHOD

A semiconductor device having a p+ collector region in the surface of an n− drift region. The p+ collector region forms a p-n junction with the n− drift region. A collector electrode is in contact with the p+ collector region. A low-lifetime region having a carrier lifetime shorter than in other regions is provided, extending from the n− drift region to the p+ collector region, at the interface between the n− drift region and p+ collector region. The low-lifetime region, being partially activated in accordance with the concentration distribution of a p-type impurity implanted in order to form the p+ collector region, is in a barely activated state. The low-lifetime region has an activation rate lower than that of the p+ collector region. The p+ collector region is completely electrically activated as far as a depth of, for example, 0.5 μm-0.8 μm, from the surface on the collector electrode side. 1. A semiconductor device comprising:a first conductivity type first semiconductor region;a second conductivity type second semiconductor region, in contact with the first semiconductor region, that forms a p-n junction with the first semiconductor region; anda low-lifetime region provided at the interface between the first semiconductor region and second semiconductor region, electrically activated in accordance with a second conductivity type impurity concentration distribution of the second semiconductor region, that has a carrier lifetime shorter than that in other regions.2. The semiconductor device according to claim 1 , wherein the low-lifetime region is provided extending from the first semiconductor region to the second semiconductor region.3. The semiconductor device according to claim 2 , wherein the low-lifetime region is provided at a depth 0.4 μm or more claim 2 , 1.2 μm or less claim 2 , from the surface on the side opposite the plane in which the second semiconductor region is in contact with the first semiconductor region.4. A semiconductor device comprising ...

METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

Mirror-polished CZ wafer and FZ wafer are prepared. A first impurity region which will be a first isolation region is formed in a surface layer of a first main surface of the CZ wafer. The first main surface of the CZ wafer and a first main surface of the FZ wafer are bonded to each other by an inter-molecular bond. A second impurity region which will be a second isolation region is formed in a surface layer of a second main surface of the FZ wafer. A heat treatment is performed to diffuse the first impurity region and the second impurity region such that the first impurity region and the second impurity region are continuous, thereby forming a through silicon isolation region. 1. A method of manufacturing a semiconductor device comprising:a first region forming step of selectively forming a first semiconductor region of a second conduction type in a surface layer of a first main surface of a first wafer which is a first conduction type;a bonding step of bonding the first main surface of the first wafer and a first main surface of a second wafer which is the first conduction type after the first region forming step to form a composite wafer;a second region forming step of selectively forming a second semiconductor region of the second conduction type in a surface layer of a second main surface of the second wafer at a position corresponding to the first semiconductor region which is formed in the first main surface of the first wafer; anda diffusion step of diffusing the first semiconductor region and the second semiconductor region such that the first semiconductor region and the second semiconductor region are continuous.2. The method of manufacturing a semiconductor device according to claim 1 , wherein claim 1 , in the second region forming step claim 1 , the second semiconductor region is formed so as to overlap the first semiconductor region in a depth direction of a wafer obtained by bonding the first wafer and the second wafer.3. The method of manufacturing ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-tRNA SYNTHETASE

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

Water resistant led devices and an led display including same

The disclosure provides an LED package including a first plastic portion having a mounting surface and a lower surface. In some embodiments, the LED package includes a second portion surrounding the first plastic portion and exposing the mounting surface and the lower surface of the first plastic portion. In other embodiments, the first plastic portion includes at least one of a hole or a protrusion and the second portion includes corresponding structure filing the hole or surrounding the protrusion of the first plastic portion. The first plastic portion and the second portion have different optical properties.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

Multi-Winding Magnetic Structures

Multi-winding magnetic structures and methods of making multi-winding magnetic structures are disclosed. A multi-winding magnetic structure includes a plurality of windings (A, B; A, B, C; A, B; A, B, C; A, B; A, B; A, B; A, B) and a core () formed of a magnetic material. The core includes a core top (), a core bottom () and a plurality of columns (A, B, C; A, B; A, B, C; A, B; A, C; ). The core top has an exterior edge () defining the shape of the core top and a central section () having a substantially constant thickness. The core bottom which is beneath the core top has an exterior edge () defining the shape of the core bottom and a central section () having a substantially constant thickness. The thickness of one of the core bottom and the core top decreases from an edge () of its central section to its exterior edge (). The plurality of columns extends from the core bottom to the core top and the plurality of windings are wound around the columns. 1. A multi-winding magnetic structure comprising: a first column, a second column and a third column, the first column and the second column spaced apart from each other to define a winding window between the first column and the second column,', 'a core top overlying the first, second and third columns and defining a top of the winding window, and', 'a core bottom underlying the first, second and third columns and defining a bottom of the winding window;, 'a magnetic core including'}a first winding positioned around the first column, the first winding including a plurality of turns of winding material, the plurality of turns of the first winding passing through the winding window; anda second winding positioned around the second column, the second winding including a plurality of turns of winding material the plurality of turns of the second winding passing through the winding window;a third winding positioned around the third column;the first winding and second winding extending in a same direction around the first ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

SEMICONDUCTOR DEVICE AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

A semiconductor device and related method of manufacturing a semiconductor device that has an active region in the inner circumference of a chip with a thickness less than that of the outer circumference of the chip in which a termination structure is provided. An n field stop region, a p collector region, and a collector electrode are on the other main surface of an n drift region. The n field stop region, the p collector region, and the collector electrode extend from the active region to the termination structure. In the termination structure, a silicon oxide film has a position from a first main surface of the n drift region in a first depth direction substantially the same as the position of the collector electrode from the first main surface of the n drift region () in the first depth direction in the active region. 1. A semiconductor device comprising:a first semiconductor region of a first conduction type;a second semiconductor region which is of a second conduction type and comes into contact with one surface of the first semiconductor region;a third semiconductor region which is of the second conduction type, comes into contact with a surface of the second semiconductor region opposite to the first semiconductor region, and has a resistivity higher than that of the second semiconductor region;a fourth semiconductor region which is of the first conduction type and is selectively provided in a surface layer of the third semiconductor region opposite to the second semiconductor region;a fifth semiconductor region which is of the second conduction type, is provided in the fourth semiconductor region, and has a resistivity lower than that of the third semiconductor region;a gate electrode which is formed on a surface of the fourth semiconductor region interposed between the third semiconductor region and the fifth semiconductor region, with a gate insulating film interposed therebetween;a first electrode which electrically connects the fourth semiconductor ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. 121-. (canceled)22. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an isolated glycyl-tRNA synthetase (GRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:1 , (b) a fragment of (a) comprising at least 600 contiguous amino acids of SEQ ID NO:1 , and (c) a variant of (a) having at least 95% identity to SEQ ID NO:1 , where the GRS polypeptide has cell signaling activity and is at least about 90% pure , and where the composition is sterile and pyrogen-free.23. The therapeutic composition of claim 22 , where the GRS polypeptide comprises at least 600 contiguous amino acids of SEQ ID NO:1 and has at least 95% identity to SEQ ID NO:1.24. The therapeutic composition of claim 23 , where the GRS polypeptide has at least 98% identity to SEQ ID NO:1.25. The therapeutic composition of claim 24 , where the GRS polypeptide comprises SEQ ID NO:1.26. The therapeutic composition of claim 22 , where the GRS polypeptide is about 685 amino acids in length.27. The therapeutic composition of claim 26 , where the GRS polypeptide consists essentially of SEQ ID NO:1.28. The therapeutic composition of claim 22 , where the GRS polypeptide is at least about 95% pure.29. The therapeutic composition of claim 22 , where the GRS polypeptide is at least about 99% pure.3026. The therapeutic composition of any of - claims 22 , where the GRS polypeptide further comprises a heterologous fusion partner.31. The therapeutic composition of claim 30 , where the heterologous fusion partner comprises an Fc region.32. The therapeutic composition of claim 22 , where the GRS polypeptide is pegylated.33. The therapeutic composition of claim 22 , where the GRS polypeptide is a recombinant polypeptide.34. The therapeutic composition of claim 33 , where the recombinant polypeptide is ...

Composition Comprising Propylene-Alpha-Olefin Copolymer, Olefin Block Copolymer and DPO-BSA Molecular Melt

Compositions comprising (A) propylene-alpha-olefin copolymer, (B) olefin block copolymer, and (C) DPO-BSA molecular melt (MM) are useful in the preparation of the top skin layer of artificial leather multi-layer structures. 1. A composition comprising (A) propylene-alpha-olefin copolymer , (B) olefin block copolymer , and (C) DPO-BSA molecular melt (MM).2. The composition of in which the propylene-alpha-olefin copolymer comprises from 20 to 90 weight percent (wt %) of the composition claim 1 , and the olefin block copolymer comprises from 20 to 90 wt % of the composition.3. The composition of in which the DPO-BSA MM comprises at least 300 parts per million (ppm) of the composition.4. The composition of in which the DPO-BSA MM comprises a coupling agent and antioxidant at a coupling agent to antioxidant mole ratio from 1:10 to 10:1.5. The composition of further comprising at least one of a styrenic block interpolymer claim 3 , a homogeneously branched ethylene/alpha-olefin interpolymer claim 3 , and a random polypropylene interpolymer.6. A top layer of an artificial leather multi-layer structure claim 3 , the top layer made from the composition of .7. An artificial leather multi-layer structure comprising the top layer made from the composition of .8. An article comprising the artificial leather multi-layer structure of .9. A process for making a composition claim 7 , the process comprising the steps of:A. Dry blending (1) a DPO-BSA molecular melt (MM), (2) a propylene-alpha-olefin copolymer, (3) an olefin block copolymer (OBC), and (4) optional ingredients;B. Compounding the dry blend of (A) under a temperature at which the propylene-alpha-olefin copolymer and OBC are melted but the MM is not activated, andC. Activating the MM so as to initiate coupling/crosslinking of the propylene-ethylene copolymer and OBC.10. The process of in which the dry blend of (A) is compounded at a temperature from 130 to 150° C. claim 9 , and the MM is activated at a temperature in ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

AMINO ACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions. 1114-. (canceled)115. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an isolated histidyl-tRNA synthetase (HRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:28 , (b) a fragment of (a) comprising at least 500 contiguous amino acids of SEQ ID NO:28 , and (c) a variant of (a) having at least 95% identity to SEQ ID NO:28 , where the HRS polypeptide has an anti-inflammatory activity and is at least about 90% pure , and where the composition is sterile and pyrogen-free.116. The therapeutic composition of claim 115 , where the HRS polypeptide comprises at least 500 contiguous amino acids of SEQ ID NO:28 and has at least 95% identity to SEQ ID NO:28.117. The therapeutic composition of claim 116 , where the HRS polypeptide has at least 98% identity to SEQ ID NO:28.118. The therapeutic composition of claim 117 , where the HRS polypeptide comprises SEQ ID NO:28.119. The therapeutic composition of claim 115 , where the HRS polypeptide is about 509 amino acids in length.120. The therapeutic composition of claim 119 , where the HRS polypeptide consists essentially of SEQ ID NO:28.121. The therapeutic composition of claim 115 , where the HRS polypeptide is at least about 95% pure.122. The therapeutic composition of claim 121 , where the HRS polypeptide is at least about 99% pure.123120. The therapeutic composition of any of - claims 115 , where the HRS polypeptide further comprises a heterologous fusion partner.124. The therapeutic composition of claim 123 , where the heterologous fusion partner comprises an Fc fragment.125. The therapeutic composition of claim 115 , ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 50 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TRYPTOPHANYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 50 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 50 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% claim ...

Miniature Surface Mount Device

A surface mount LED package includes a lead frame carrying a plurality of LEDs and a plastic casing at least partially encasing the lead frame. The lead frame includes an electrically conductive chip carrier and first, second, and third electrically conductive connection parts separate from the electrically conductive chip carrier. Each of the first, second and third electrically conductive connection parts has an upper surface, a lower surface, and a connection pad on the upper surface. The plurality of LEDs are disposed on an upper surface of the electrically conductive chip carrier. Each LED has a first electrical terminal electrically coupled to the electrically conductive chip carrier. Each LED has a second electrical terminal electrically coupled to the connection pad of a corresponding one of the first, second, and third electrically conductive connection parts.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a cellular ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a cellular ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a cellular ...

METHOD AND APPARATUS FOR DISPLAYING INTERACTIVE ATTRIBUTES DURING MULTIMEDIA PLAYBACK

The disclosure relates to methods and apparatuses for displaying interactive attributes. The method comprises: determining interactive attributes regarding a multimedia resource based on interactive data of a user during playback of the multimedia resource; generating visualized interactive information based on the interactive attributes; and displaying the visualized interactive information. According to embodiments of the disclosure, interactive attributes can be determined based on interactive data of a user during playback of a multimedia resource, and then visualized interactive information is generated and displayed, to clearly and intuitively display interactions, improve the display effect, and enhance user experience. 117-. (canceled)18. A method comprising:determining interactive attributes regarding a multimedia resource based on interactive data of a user input during playback of the multimedia resource;generating visualized interactive information based on the interactive attributes; anddisplaying the visualized interactive information during subsequent playback of the multimedia resource.19. The method of claim 18 , the interactive data comprising comment icons and corresponding input times claim 18 , the interactive attributes comprising at least one of an input time distribution of a first comment icon or an overall input time distribution for multiple comment icons.20. The method of claim 19 , the comment icons comprising comment icons in a bullet screen.21. The method of claim 19 , the generating visualized interactive information comprising at least one of:generating, based on the interactive attributes, an overall icon input time density graph for multiple comment icons; orgenerating, based on the interactive attributes, a first icon input time density graph for the one or a plurality of first comment icons.22. The method of claim 19 , the generating visualized interactive information comprising:determining, based on the interactive attributes, a ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1139-. (canceled)140. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.141. The therapeutic composition of claim 140 , wherein the AARS polypeptide is selected from Table E7.142. The therapeutic composition of claim 140 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.143. The therapeutic composition of claim 140 , wherein the antibody is a humanized antibody.144. The therapeutic composition of claim 140 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.145. The therapeutic composition of claim 140 , wherein the composition is a sterile claim 140 , freeze-dried powder.146. The therapeutic composition of claim 140 , wherein the composition is a sterile injectable solution.147. The therapeutic composition of claim 140 , wherein the composition is buffered and comprises an isotonic agent.148. The therapeutic composition of claim 140 , wherein the composition is suitable for intravenous claim 140 , intramuscular claim 140 , subcutaneous claim 140 , or intraperitoneal administration.149. The therapeutic composition of claim 140 , wherein the composition comprises a surfactant.150. The therapeutic composition of claim 140 , wherein the composition has a purity of at least about 95% on a protein basis.151. A method of modulating a cellular ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-tRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has an extracellular signaling activity and a solubility of at least about 5 μg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of or differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.129. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.130. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of that is at least 80% identical to a sequence in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9.131. The isolated AARS polypeptide of claim 130 , wherein the AARS polypeptide is fused to a heterologous polypeptide.132. A system claim 130 , comprising an aminoacyl-tRNA synthetase (AARS) polypeptide of claim 130 , and an element selected from the group consisting of(i) a binding partner that binds to the AARS polypeptide,(ii) an ...

Semiconductor device and production method for semiconductor device

Depth of a termination p base region provided in a termination portion of an active region close to an edge termination structure portion is more than depth of a p-type base region provided inside the termination p base region. An n-type high-concentration region is provided from one main surface of the semiconductor substrate in the entire surface layer of one surface of a semiconductor substrate within a depth of 20 μm or less below the bottom of the termination p base region. Ratio of the impurity concentration n 1 of the n-type high-concentration region ( 1 c) to the impurity concentration n 2 of an n − drift region satisfies 1.0<n 1 /n 2 ≦5.0. Reverse leakage current when operation temperature of an element is high can be reduced and trade-off between on-state voltage and switching loss can be improved. Rising peak voltage of collector voltage when a semiconductor device is off is reduced.

METHOD AND APPARATUS FOR RECOMMENDING ASSOCIATED USER BASED ON INTERACTIONS WITH MULTIMEDIA PROCESSES

The disclosure relates to a method and an apparatus for recommending an associated user. In one embodiment a method comprises determining a first interactive attribute of a first user based on first interactive data of the first user in a multimedia resource playing process; determining interactive relevance between the first user and a second user according to the first interactive attribute and a second interactive attribute of the second user; and recommending, according to the interactive relevance, the second user associated with the first user. Embodiments according to the disclosure can determine an interactive attribute based on interactive data, determine interactive relevance between a first user and a second user according to the interactive attribute, and further recommend the second user associated with the first user, thereby recommending associated users based on user behavior, improving the accuracy in recommending associated users, and enhancing user experience. 119-. (canceled)20. A method comprising:determining a first interactive attribute of a first user based on first interactive data of the first user during a multimedia resource playing process;determining interactive relevance between the first user and at least one second user based on the first interactive attribute and a second interactive attribute of the second user; andrecommending, based on the interactive relevance, the second user to the first user.21. The method of claim 20 , further comprising determining the second interactive attribute of the second user based on second interactive data of the second user in the multimedia resource playing process.22. The method of claim 21 , the first interactive data comprising a comment icon input by the first user in the multimedia resource playing process and a corresponding input time; the first interactive attribute of the first user comprising one or a plurality of an input frequency of the first user for a first comment icon claim 21 , ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME

A semiconductor device includes a first semiconductor region of a second conductivity type selectively formed in the main surface of the semiconductor substrate of a first conductivity type so as to be between a front surface structure of a first semiconductor element and a front surface structure of a second semiconductor element and so as to surround the front surface structure of the first semiconductor element and the front surface structure of the second semiconductor element; a second semiconductor region of the first conductivity type in the main surface of the semiconductor substrate outside the first semiconductor region and separated therefrom; and at least one trench filled with an insulating layer in the first semiconductor region between the first semiconductor element and the second semiconductor element, forming an isolation structure isolating the front surface structure of the first semiconductor element from the front surface structure of the second semiconductor element.

POWER CONVERSION APPARATUS

A power conversion apparatus includes N semiconductor modules respectively including a switch part including first and second semiconductor switches coupled in series, and an output terminal coupled to a node that connects the first and second semiconductor switches, where N is an integer greater than or equal to 3, wherein the N semiconductor modules are arranged so that the output terminals thereof are adjacent to each other. The power conversion apparatus further includes an output bar to couple the output terminals of the N semiconductor modules so that a parasitic inductance of a current path coupling the output terminals of first and second semiconductor modules among the N semiconductor modules, and a parasitic inductance of a current path coupling the output terminals of the first and third semiconductor modules among the N semiconductor modules, are approximately balanced. 1. A power conversion apparatus comprising: a switch part including a first semiconductor switch and a second semiconductor switch that are coupled in series, and', 'an output terminal coupled to a node that electrically connects the first semiconductor switch and the second semiconductor switch,', 'wherein four output terminals of the first,, 'a first semiconductor module, a second semiconductor module, a third semiconductor module, and a fourth semiconductor module respectively including'}second, third, and fourth semiconductor modules are arranged in an array of two rows by two columns along two mutually perpendicular directions in a plan view; andan output bar having an approximate X-shape in the plan view, and configured to electrically connect the four output terminals of the first, second, third, and fourth semiconductor modules via four tip ends of the approximate X-shape, so that a length of a current path of the output bar electrically connecting any two output terminals among the four output terminals is approximately constant.2. The power conversion apparatus as claimed in ...

SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING THE SEMICONDUCTOR DEVICE, AND METHOD FOR CONTROLLING THE SEMICONDUCTOR DEVICE

An A-NPC circuit is configured so that the intermediate potential of two connected IGBTs is clamped by a bidirectional switch including two RB-IGBTs. Control is applied to the turn-on di/dt of the IGBTs during the reverse recovery of the RB-IGBTs. The carrier life time of an n drift region in each RB-IGBT constituting the bidirectional switch is comparatively longer than that in a typical NPT structure device. A low life time region is also provided in the interface between the n drift region and a p collector region, and extends between the n drift region and the p collector region. Thus, it is possible to provide a low-loss semiconductor device, a method for manufacturing the semiconductor device and a method for controlling the semiconductor device, in which the reverse recovery loss is reduced while the reverse recovery current peak and the jump voltage peak during reverse recovery are suppressed. 1. A semiconductor device comprising:a first semiconductor region of a first conductivity type;a second semiconductor region of a second conductivity type which is selectively provided in a surface layer of one side of the first semiconductor region;a third semiconductor region of the first conductivity type which is selectively provided inside the second semiconductor region;a gate electrode which is provided in a surface of a portion of the second semiconductor region which is located between the first semiconductor region and the third semiconductor region, a gate insulating film being put between the gate electrode and the second semiconductor region;a fourth semiconductor region of the second conductivity type which is provided on another side of the first semiconductor region;a low life time region which is provided in an interface between the first semiconductor region and the fourth semiconductor region and which is shorter in carrier life time than any other region;a fifth semiconductor region of the second conductivity type which is provided in an outer ...

METHOD AND DEVICE FOR CATEGORIZING MULTIMEDIA RESOURCES

The present disclosure relates to a method and a device for categorizing multimedia resources. The method includes: counting the numbers of icons for respective types of icons input by a user for a multimedia resource; and determining a category to which the multimedia resource belongs according to the numbers of the respective types of icons input for the multimedia resource. The method and device for categorizing multimedia resources according to the present disclosure can take respective types of icons input by the user for the multimedia resources into consideration when categorizing the multimedia resources, thereby improving the accuracy of the categorization of the multimedia resources. 1. A method for categorizing a multimedia resource , comprising:collecting input from one or more of a plurality of client devices associated with presentation of the multimedia resource on the client devices, the input indicating one or more icons, where each icon is associated with a corresponding type;counting numbers of icons for respective types of icons;determining, at a server device, a category to which the multimedia resource belongs according to the numbers of the respective types of icons input for the multimedia resource; andassociating category information representing the determined category with the multimedia resource.2. The method according to claim 1 , wherein the method further comprises storing respective input times for at least some of the icons claim 1 , andcounting numbers of icons for respective types of icons comprises counting numbers of icons for respective types of icons included in the collected input having input times within a particular time period, where the particular time period starts no earlier than a time of release of the multimedia resource and ends such that a subset of fewer than all icons input by all of the plurality of client devices have input times within the particular time period.3. The method according to claim 1 , wherein the ...

Micro light emitting device and display apparatus

A micro light emitting device including a component layer, a first electrode and a second electrode is provided. The component layer includes a main body and a protruding structure disposed on the main body. The first electrode is electrically connected to the component layer. The second electrode is electrically connected to the component layer. The first electrode, the second electrode and the protruding structure are disposed on the same side of the main body. The protruding structure is located between the first electrode and the second electrode. A connection between the first electrode and the second electrode traverses the protruding structure. The main body has a surface. The protruding structure has a first height with respect to the surface. Any one of the first electrode and the second electrode has a second height with respect to the surface. The relation 0.8≤H1/H2≤1.2 is satisfied, wherein H1 is the first height and H2 is the second height. A display apparatus having a plurality of micro light emitting devices is provided as well.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED PROTEIN FRAGMENTS OF TRYPTOPHANYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A pharmaceutical composition , comprising an isolated polynucleotide that encodes an aminoacyl-tRNA synthetase (AARS) polypeptide of up to 280 amino acids in length that comprises an amino acid sequence which is at least 95% identical to SEQ ID NO:16 , 48 , or 56 , wherein the polynucleotide is selected from (a) a cDNA polynucleotide and (b) a modified mRNA polynucleotide , wherein the AARS polypeptide has an extracellular signaling activity , and wherein the composition is substantially endotoxin-free.127. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide comprises the amino acid sequence of SEQ ID NO:16 claim 126 , 48 claim 126 , or 56.128. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide is up to 260 amino acids in length and comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:16 or 56.129. The pharmaceutical composition of claim 128 , wherein the AARS polypeptide comprises the amino acid sequence of SEQ ID NO: 16 or 56.130. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide is up to 160 amino acids in length and comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:56.131. The pharmaceutical composition of claim 130 , wherein the AARS polypeptide comprises the amino acid sequence of SEQ ID NO:56.132. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide consists of SEQ ID NO:16 claim 126 , 48 claim 126 , or 56 or differs from SEQ ID NO:16 claim 126 , 48 claim 126 , or 56 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A pharmaceutical composition , comprising an isolated polynucleotide that encodes an aminoacyl-tRNA synthetase (AARS) polypeptide fragment of 100-150 amino acids in length that comprises an amino acid sequence which is at least 95% identical to SEQ ID NO:64 or a fragment thereof which is at least 95% identical to SEQ ID NO:83 , wherein the polynucleotide is selected from (a) a cDNA polynucleotide and (b) a modified mRNA polynucleotide , wherein the AARS polypeptide has an extracellular signalling activity , and wherein the composition is substantially endotoxin-free.127. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide fragment comprises the amino acid sequence of SEQ ID NO:64 or a fragment thereof which comprises the amino acid sequence of SEQ ID NO:83.128. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide fragment is at least 95% identical to SEQ ID NO:64 or 83.129. The pharmaceutical composition of claim 128 , wherein the AARS polypeptide fragment is at least 95% identical to SEQ ID NO:64.130. The pharmaceutical composition of claim 128 , wherein the AARS polypeptide fragment is at least 95% identical to SEQ ID NO:83.131. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide fragment consists of SEQ ID NO:64 or 83 or differs from SEQ ID NO:64 or 83 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , or 5 amino acids.132. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide fragment is fused to a heterologous polypeptide.133. The pharmaceutical composition of claim 132 , wherein the heterologous ...

SEMICONDUCTOR DEVICE AND SEMICONDUCTOR DEVICE MANUFACTURING METHOD

An n-type low lifetime adjustment region is provided in a portion inside an n type drift region deeper than the bottom surface of a termination p-type base region or p-type guard ring from a substrate front surface, separated from the termination p-type base region and the p-type guard ring. The carrier lifetime of the n-type low lifetime adjustment region is shorter than the carrier lifetime of the n type drift region. Because of this, it is possible to provide a reverse blocking IGBT such that it is possible to suppress both a high temperature reverse leakage current and an increase in turn-off loss, while suppressing deterioration in the trade-off relationship between the turn-off loss and the on-state voltage. 1. A semiconductor device , comprising: an insulated gate structure having a second conductivity type base region selectively provided on a first main surface side of a first conductivity type semiconductor substrate,', 'a first conductivity type emitter region selectively provided inside the second conductivity type base region, and', 'a gate electrode provided across a gate dielectric on the surface of a portion of the second conductivity type base region sandwiched by a drift region formed of the first conductivity type semiconductor substrate and the first conductivity type emitter region;, 'an active region includingan edge termination structure portion surrounding the outer periphery of the active region;a second conductivity type collector layer provided on a second main surface side of the first conductivity type semiconductor substrate;a second conductivity type isolation layer provided in an outer peripheral portion of the edge termination structure portion so as to link the first main surface and the second main surface of the first conductivity type semiconductor substrate and electrically connected to the second conductivity type collector layer; anda first conductivity type low lifetime adjustment region provided separated from the second ...

SEMICONDUCTOR DEVICE AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

A semiconductor device is provided, the semiconductor device including a base layer of a first conductivity type having a MOS gate structure formed on a front surface side thereof, a collector layer of a second conductivity type formed on a rear surface side of the base layer, and into which a first dopant and a second dopant which is different from the first dopant are implanted, and a collector electrode formed on a rear surface side of the collector layer, wherein an impurity concentration peak of the second dopant is at a deeper position from the rear surface of the collector layer than an impurity concentration peak of the first dopant, and magnitude of the impurity concentration peak of the second dopant is larger than 1/100 of magnitude of the impurity concentration peak of the first dopant. 1. A semiconductor device comprising:a base layer of first conductivity type having a MOS gate structure formed on a front surface side thereof;a collector layer of a second conductivity type formed on a rear surface side of the base layer, and into which a first dopant and a second dopant which is different from the first dopant are implanted; anda collector electrode formed on a rear surface side of the collector layer,{'b': 1', '100, 'wherein an impurity concentration peak of the second dopant is at a deeper position from the rear surface of the collector layer than an impurity concentration peak of the first dopant, and magnitude of the impurity concentration peak of the second dopant is larger than / of magnitude of the impurity concentration peak of the first dopant.'}2. The semiconductor device according to claim 1 , wherein the collector layer has a layer having an impurity concentration which is 1.0×10or less between the impurity concentration peak of the first dopant and the impurity concentration peak of the second dopant.3. The semiconductor device according to claim 1 , wherein the collector layer has a layer having an impurity concentration with magnitude ...

GATE DRIVE CIRCUIT, DRIVE DEVICE, SEMICONDUCTOR DEVICE, AND GATE DRIVE METHOD

A gate drive circuit includes: a drive unit configured to drive a gate of a main circuit element including a majority carrier device; and a drive capability change unit configured to cause the drive unit to increase a drive capability of turning on the main circuit element as a main circuit current that flows through the main circuit element decreases. 1. A gate drive circuit comprising:a drive unit configured to drive a gate of a main circuit element including a majority carrier device; anda drive capability change unit configured to cause the drive unit to increase a drive capability of turning on the main circuit element as a main circuit current that flows through the main circuit element decreases.2. The gate drive circuit according to claim 1 , wherein the drive capability change unit is configured to cause the drive unit to decrease the drive capability of turning on the main circuit element as a temperature of the main circuit element increases.3. The gate drive circuit according to claim 1 , wherein the drive capability change unit is configured to cause the drive unit to increase the drive capability of turning off the main circuit element as a temperature of the main circuit element increases.4. The gate drive circuit according to claim 1 ,wherein the drive capability change unit includes a drive resistor that is connected to the gate of the main circuit element or includes a current source for causing a drive current to flow to the gate of the main circuit element, andwherein the drive capability change unit is configured to cause the drive unit to increase the drive capability of turning on or off the main circuit element, by reducing a resistance value of the drive resistor or increasing a current value of the drive current.5. The gate drive circuit according to claim 1 ,wherein the main circuit element includes a switching element and a diode that is connected in antiparallel to the switching element, andwherein the switching element and the diode are ...

Semiconductor device and semiconductor device manufacturing method

An n − type drift region, an n-type field stop region, and an n − type FZ wafer are provided in an n − type wafer. An edge termination structure portion is provided in a chip outer peripheral portion of regions of the n − type wafer, surrounding an active region inside a chip inner portion. A thickness of the chip inner portion is less than a thickness of the chip outer peripheral portion owing to a groove. A p-type collector region is in contact with the n − type FZ wafer and n-type field stop region. A collector electrode is in contact with the p-type collector region. A second distance between the collector electrode and the n-type field stop region in the edge termination structure portion is greater than a first distance between the collector electrode and the n-type field stop region in the active region.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a cellular ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-6 or 9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide has an extracellular signaling activity.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of an amino acid sequence set forth in any of Table(s) 1-6 or 9 or differs from an amino acid sequence set forth in any of Table(s) 1-6 or 9 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% claim 126 , 85% claim 126 , 90% claim 126 , 95% claim 126 , 98% claim 126 , or 100% identical to an amino acid sequence set forth in any of Table(s) 1-6 or 9.132. The isolated AARS polypeptide of claim 131 , wherein the AARS polypeptide is fused to a heterologous polypeptide.133. A system claim 131 , comprising an AARS polypeptide of claim 131 , and an element ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-TRNA SYNTHETASE

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide has an extracellular signaling activity.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of an amino acid sequence set forth in any of Table(s) 1-9 or differs from an amino acid sequence set forth in any of Table(s) 1-9 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% claim 126 , 85% claim 126 , 90% claim 126 , 95% claim 126 , 98% claim 126 , or 100% identical to an amino acid sequence set forth in any of Table(s) 1-9.132. The isolated AARS polypeptide of claim 131 , wherein the AARS polypeptide is fused to a heterologous polypeptide.133. The isolated AARS polypeptide of claim 131 , further comprising an element selected from the group ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1132-. (canceled)133. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.134. The therapeutic composition of claim 133 , wherein the AARS polypeptide is selected from Table E7.135. The therapeutic composition of claim 133 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.136. The therapeutic composition of claim 133 , wherein the antibody is a humanized antibody.137. The therapeutic composition of claim 133 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.138. The therapeutic composition of claim 133 , wherein the composition is a sterile claim 133 , freeze-dried powder.139. The therapeutic composition of claim 133 , wherein the composition is a sterile injectable solution.140. The therapeutic composition of claim 133 , wherein the composition is buffered and comprises an isotonic agent.141. The therapeutic composition of claim 133 , wherein the composition is suitable for intravenous claim 133 , intramuscular claim 133 , subcutaneous claim 133 , or intraperitoneal administration.142. The therapeutic composition of claim 133 , wherein the composition comprises a surfactant.143. The therapeutic composition of claim 133 , wherein the composition has a purity of at least about 95% on a protein basis.144. A method of modulating a cellular ...

MICRO LIGHT-EMITTING DIODE

A micro light-emitting diode is provided. The micro light-emitting diode includes a first-type semiconductor layer having a first doping type; a light-emitting layer over the first-type semiconductor layer; a first-type electrode over the first-type semiconductor layer; a second-type semiconductor layer having a second doping type over the light-emitting layer, wherein the second doping type is different from the first doping type; a second-type electrode over the second-type semiconductor layer; and a barrier layer under the first-type semiconductor layer and away from the first-type electrode and the second-type electrode, wherein the barrier layer includes a doped region having the second doping type.

COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. 121-. (canceled)22. A pharmaceutical composition , comprising a pharmaceutically-acceptable carrier and an isolated RNA polynucleotide having at least one modified nucleotide , wherein the isolated RNA polynucleotide encodes a glycyl-tRNA synthetase (GRS) polypeptide that comprises amino acid residues 367-438 of SEQ ID NO:1 , or a GRS variant that comprises a sequence at least 95% identical to residues 367-438 of SEQ ID NO:1.23. The pharmacuetical composition of claim 22 , wherein the GRS polypeptide comprises the sequence set forth in SEQ ID NO:1 or the GRS variant comprises a sequence at least 95% identical to SEQ ID NO:1.24. The pharmaceutical composition of claim 23 , wherein the GRS polypeptide comprises the sequence set forth in SEQ ID NO:1.25. The pharmaceutical composition of claim 22 , wherein the GRS polypeptide is up to about 500 amino acids in length and comprises amino acid residues 367-438 of SEQ ID NO:1 claim 22 , or is a GRS variant of up to about 500 amino acids in length that comprises a sequence at least 95% identical to residues 367-438 of SEQ ID NO:1.26. The pharmacuetical composition of claim 25 , wherein the GRS polypeptide comprises amino acid residues 367-438 of SEQ ID NO:1.27. The pharmacuetical composition of claim 25 , wherein the GRS polypeptide comprises amino acid residues 214-438 claim 25 , 214-685 claim 25 , 239-685 claim 25 , 265-685 claim 25 , 311-685 claim 25 , or 333-685 of SEQ ID NO:1 claim 25 , or wherein the GRS variant comprises a sequence at least 95% identical to residues 214-438 claim 25 , 214-685 claim 25 , 239-685 claim 25 , 265-685 claim 25 , 311-685 claim 25 , or 333-685 of SEQ ID NO:1.28. The pharmacuetical composition of claim 27 , wherein the GRS polypeptide comprises amino acid residues 214-438 claim 27 , 214-685 claim 27 , 239-685 claim 27 , ...

Aminoacyl trna synthetases for modulating inflammation

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

HALOGEN-FREE, FLAME RETARDANT COMPOSITION FOR WIRE AND CABLE APPLICATIONS

A halogen-free, flame retardant composition comprises: A. A polymer blend comprising: 1. Polypropylene, and 2. Thermoplastic elastomer (TPE) other than the polypropylene of (A)(1), and B. An intumescent flame retardant comprising at least one of: 1. A compound of Formula 1 where M is at least one of melamine, morpholine, piperazine, piperidine, alkyl hydroxyl and a triazine polymer of Formula 2 where D is a heterocyclic or polyamine moiety, and m and n are independently integers the sum (m+n) of which is less than 1000, and 2. A piperazine phosphate. 2. A composition comprising: 1. Polypropylene, and', '2. Thermoplastic elastomer (TPE) other than the polypropylene of (A)(1), and, 'A. A polymer blend comprisingB. An intumescent flame retardant comprising piperazine phosphate.4. The composition of comprising from 5 to 80 weight percent polypropylene and from 5 to 80 weight percent TPE.5. (canceled)6. The composition of comprising from 1 to 70 weight percent of the intumescent flame retardant.7. The composition of in which the polypropylene of (A)(1) is impact-modified polypropylene claim 1 , and the TPE is at least one of a styrenic block copolymer claim 1 , an ethylene-based elastomer or plastomer claim 1 , an ethylene block copolymer and a propylene-based plastomer or elastomer.8. The composition of in which the intumescent flame retardant further comprises one or more of halogen-free organic phosphonic acids claim 1 , phosphonates claim 1 , phosphinates claim 1 , phosphonites claim 1 , phosphinites claim 1 , phosphine oxides claim 1 , phosphines claim 1 , phosphites claim 1 , phosphates claim 1 , phosphonitrilics claim 1 , phosphorus ester amides claim 1 , phosphoric acid amides claim 1 , phosphonic acid amides claim 1 , phosphinic acid amides claim 1 , melamine and melamine derivatives claim 1 , pentaerythritol claim 1 , triglyceride isocyanurate claim 1 , novolac and a metal oxide or salt.9. The composition of in which the metal oxide is zinc oxide.10. A wire or ...

CRYSTAL FORMS C AND E OF PYRAZIN-2(1H)-ONE COMPOUND AND PREPARATION METHOD THEREFOR

A crystal form of a pyrazin-2(1H)-one compound and a preparation method therefor. The present invention specifically related to a compound of formula (II) and a preparation method for a crystal form of the compound. 3. The hydrochloride salt as defined in claim 2 , wherein claim 2 , n is selected from 0.6 claim 2 , 0.7 claim 2 , 0.8 claim 2 , 0.9 claim 2 , 1 claim 2 , 1.1 claim 2 , 1.2 claim 2 , 1.3 claim 2 , 1.4 claim 2 , 1.5 claim 2 , 1.6 claim 2 , 1.7 claim 2 , 1.8 claim 2 , 1.9 and 2.4. The hydrochloride salt as defined in claim 3 , wherein n is selected from 0.9 claim 3 , 1 and 1.1.6. A crystal form C of the hydrochloride salt as defined in claim 3 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 5.24±0.20° claim 3 , 9.58 ±0.20° claim 3 , and 10.45±0.20°.7. The crystal form C as defined in claim 6 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 5.24±0.20° claim 6 , 9.58±0.20° claim 6 , 10.45±0.20° claim 6 , 14.26±0.20° claim 6 , 20.86±0.20° claim 6 , 24.99±0.20° claim 6 , 26.21±0.20° and 27.71±0.20°.8. The crystal form C as defined in claim 7 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 5.24° claim 7 , 8.45° claim 7 , 9.08° claim 7 , 9.58° claim 7 , 10.45° claim 7 , 11.49° claim 7 , 13.23° claim 7 , 14.02° claim 7 , 14.26° claim 7 , 15.18° claim 7 , 15.60° claim 7 , 16.35° claim 7 , 18.15° claim 7 , 18.74° claim 7 , 19.52° claim 7 , 19.94° claim 7 , 20.86° claim 7 , 21.65° claim 7 , 21.97° claim 7 , 22.50° claim 7 , 23.28° claim 7 , 23.64° claim 7 , 24.16° claim 7 , 24.99° claim 7 , 26.21° claim 7 , 26.98° claim 7 , 27.71° claim 7 , 28.52° claim 7 , 29.07° claim 7 , 29.43° claim 7 , 30.37° claim 7 , 31.72° claim 7 , 32.30° claim 7 , 33.11° claim 7 , 34.79° and 36.78°.9. The crystal form C as defined in claim 8 , wherein the X-ray ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide has an extracellular signaling activity.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of an amino acid sequence set forth in any of Table(s) 1-9 or differs from an amino acid sequence set forth in any of Table(s) 1-9 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% claim 126 , 85% claim 126 , 90% claim 126 , 95% claim 126 , 98% claim 126 , or 100% identical to an amino acid sequence set forth in any of Table(s) 1-9.132. The isolated AARS polypeptide of claim 131 , wherein the AARS polypeptide is fused to a heterologous polypeptide.133. A system claim 131 , comprising an AARS polypeptide of claim 131 , and an element selected from the group ...

Halogen-Free Flame Retardant TPU Composition for Wire and Cable

The present disclosure provides a wire or cable comprising a flame retardant-free thermoplastic inner sheath and an outer sheath composition comprising, based on the weight of the composition, (a) 10 wt % to 90 wt % of a TPU based resin, (b) 5 wt % to 90 wt % of a metal hydrate, (c) 2 wt % to 50 wt % of a nitrogen-based phosphorus flame retardant, and (d) 2 wt % to 50 wt % liquid phosphate modifier, wherein the outer sheath is in contact with the insulation covering, and wherein the outer sheath has a thickness from greater than zero to 0.8 mm. 1. A cable comprising:a flame retardant-free thermoplastic inner sheath; and (a) 10 wt % to 90 wt % of a TPU based resin,', '(b) 5 wt % to 90 wt % of a metal hydrate,', '(c) 2 wt % to 50 wt % of a nitrogen-based phosphorus flame retardant, and', '(d) 2 wt % to 20 wt % of a liquid phosphate modifier,, 'an outer sheath composition comprising, based on the total weight of the composition,'}wherein the outer sheath is in contact with the inner sheath,wherein the outer sheath has a thickness greater than zero to 0.8 mm.2. The wire or cable of wherein the outer sheath comprises(a) 30 wt % to 50 wt % of a TPU based resin,(b) 20 wt % to 40 wt % of a metal hydrate,(c) 5 wt % to 20 wt % of a nitrogen-based phosphorus flame retardant, and(d) 3 wt % to 10 wt % of a liquid phosphate modifier.3. The wire or cable of wherein the metal hydrate is aluminum trihydrate.4. The wire or cable of wherein the nitrogen-based phosphorus flame retardant is selected from the group consisting of ammonium polyphosphate (APP) claim 1 , melamine polyphosphate (MPP) claim 1 , and piperazine pyrophosphate.5. The wire or cable of wherein the liquid phosphate modifier is selected from the group consisting of resorcinol diphenol phosphate (RDP) claim 1 , bisphenol A diphosphate (BDP) claim 1 , triphenol phosphate (TPP) claim 1 , tributoxyethyl phosphate (TBEP) claim 1 , and resorcinol bis(xylenol phosphate) (XDP).6. The wire or cable of wherein the outer sheath ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-tRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-2 , or Table(s) 4-6 , and Table(s) 7 or 79 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of ...

Semiconductor device

A semiconductor device including: a first conductivity type n-type drift layer; a second conductivity type VLD region which is formed on a chip inner circumferential side of a termination structure region provided on one principal surface of the n-type drift layer and which is higher in concentration than the n-type drift layer; a second conductivity type first clip layer which is formed on a chip outer circumferential side of the VLD region so as to be separated from the VLD region and which is higher in concentration than the n-type drift layer; and a first conductivity type channel stopper layer which is formed on a chip outer circumferential side of the first clip layer so as to be separated from the first clip layer and which is higher in concentration than the n-type drift layer. Thus, it is possible to provide a semiconductor device having a stable and high breakdown voltage termination structure in which the length of a termination structure region is small as well as the immunity to the influence of external charge is high.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A pharmaceutical composition , comprising an isolated polynucleotide that encodes an aminoacyl-tRNA synthetase (AARS) polypeptide that that consists of SEQ ID NO: 151 or differs from SEQ ID NO: 151 by substitution , deletion , and/or addition of 1 , 2 , or 3 amino acids , wherein the polynucleotide is selected from (a) a cDNA polynucleotide and (b) a modified mRNA polynucleotide , and wherein the composition has less than about 10 EU endotoxin/mg protein.127. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide consists of SEQ ID NO: 151.128. The pharmaceutical composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.129. The pharmaceutical composition of claim 128 , wherein the heterologous polypeptide is selected from the group consisting of purification tags claim 128 , epitope tags claim 128 , targeting sequences claim 128 , signal peptides claim 128 , membrane translocating sequences claim 128 , and pharmacokinetic (PK) property modifiers.130. The pharmaceutical composition of claim 126 , wherein the isolated polynucleotide comprises one or more transcriptional and/or translational control elements.131. The pharmaceutical composition of claim 126 , wherein the isolated polynucleotide is a modified mRNA polynucleotide comprising at least one modified base.132. The pharmaceutical composition of claim 126 , wherein the isolated polynucleotide is formulated for delivery encapsulated in a lipid particle claim 126 , a liposome claim 126 , a vesicle claim 126 , a nanosphere claim 126 , or a nanoparticle.133. The pharmaceutical composition of claim 126 , which is suitable for intravenous administration. This ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a ...

OPTICAL QUANTIFICATION OF INTERFACIAL CHARGE STATES

Methods of generating second harmonic generation (SHG) signals from interfaces formed with, or formed over, a noncentrosymmetric material, e.g., α-quartz, are provided. The methods make use of the noncentrosymmetric material as an internal phase reference for the determination of a variety of interfacial electrostatic parameters, including interfacial potential, interfacial charge density, and the sign of the interfacial charge (i.e., net positive or net negative). 1. A method of probing an interface , the method comprising:(a) illuminating an interface formed between a noncentrosymmetric material having a selected orientation angle with respect to a reference axis and a different material, or formed between two different materials and disposed over the noncentrosymmetric material, with light having a frequency under conditions to generate a second harmonic generation (SHG) signal having frequency 2ω, and(b) detecting the SHG signal, the SHG signal comprising a bulk second harmonic signal from the noncentrosymmetric material and an interfacial second harmonic signal from the interface.2. The method of claim 1 , further comprising (c) claim 1 , comparing the detected SHG signal to a SHG signal generated from a reference interface formed between the noncentrosymmetric material and a reference material at the selected orientation angle.3. The method of claim 1 , wherein the noncentrosymmetric material is α-quartz.4. The method of claim 1 , wherein the noncentrosymmetric material is provided as a substrate composed entirely of the noncentrosymmetric material.5. The method of claim 1 , wherein the noncentrosymmetric material is provided as a film on a supporting substrate.6. The method of claim 5 , wherein the supporting substrate comprises a centrosymmetric material.7. The method of claim 1 , wherein the selected orientation angle is that which maximizes the constructive interference claim 1 , or maximizes the destructive interference claim 1 , between the bulk second ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide has an extracellular signaling activity.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of an amino acid sequence set forth in any of Table(s) 1-9 or differs from an amino acid sequence set forth in any of Table(s) 1-9 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% claim 126 , 85% claim 126 , 90% claim 126 , 95% claim 126 , 98% claim 126 , or 100% identical to an amino acid sequence set forth in any of Table(s) 1-9.132. The isolated AARS polypeptide of claim 131 , wherein the AARS polypeptide is fused to a heterologous polypeptide.133. A system claim 131 , comprising an AARS polypeptide of claim 131 , and an element selected from the group ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a ...

AMINOACYL TRNA SYNTHETASES FOR MODULATING INFLAMMATION

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions. 1124-. (canceled)125. A method for reducing inflammation of the respiratory system in a subject in need thereof , comprising administering to the subject a sterile composition , comprising a pharmaceutically-acceptable carrier and an isolated histidyl-tRNA synthetase (HRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:28 , (b) a fragment of (a) comprising at least 400 contiguous amino acids of SEQ ID NO:28 , and (c) a variant which differs from SEQ ID NO:28 by less than 10% of the residues of SEQ ID NO:28 , wherein the HRS polypeptide has an anti-inflammatory activity and is at least about 90% pure.126. The method of claim 125 , wherein (b) is a fragment of SEQ ID NO:28 comprising at least 500 contiguous amino acids of SEQ ID NO:28.127. The method of claim 125 , wherein (c) is a variant which differs from SEQ ID NO:28 by less than 5% of the residues of SEQ ID NO:28.128. The method of claim 125 , wherein the subject in need thereof has inflammatory lung disease (ILD) claim 125 , acute respiratory distress syndrome (ARDS) claim 125 , or pneumonia.129. The method of claim 125 , wherein the subject in need thereof has fibrosis claim 125 , sarcoidosis claim 125 , rheumatoid arthritis claim 125 , lupus erythematosus claim 125 , polymyositis claim 125 , dermatomyositis claim 125 , graft vs. host disease claim 125 , scleroderma claim 125 , hypersensitivity claim 125 , or microscopic polyangiitis.130. The method of claim 125 , wherein the subject in need thereof has a condition selected from atopic asthma claim 125 , non-atopic asthma claim 125 , allergic asthma claim 125 , atopic bronchial IgE- ...

ORGANIC ELECTRONIC LIGHT EMITTING DEVICE AND METHOD OF FABRICATING THE SAME

An organic electronic light emitting device comprises a substrate; a first gate electrode formed on an upper surface of the substrate; a first insulating layer formed on the upper surface of the substrate and covering the first gate electrode; an organic layer formed on an upper surface of the first insulating layer and comprising at least two organic layers with different conductive type; a second insulating layer formed on an upper surface of the organic layer; a second gate electrode formed on an upper surface of the second insulating layer; and a source electrode and a drain electrode formed between the first and second insulating layers, and the source and drain electrodes located on both sides of the organic layer respectively. 1. An organic electronic light emitting device , comprising:a substrate;a first gate electrode formed on an upper surface of the substrate;a first insulating layer formed on the upper surface of the substrate and covering the first gate electrode;an organic layer formed on an upper surface of the first insulating layer and comprising at least two organic layers with different conductive type;a second insulating layer formed on an upper surface of the organic layer;a second gate electrode formed on an upper surface of the second insulating layer; anda source electrode and a drain electrode formed between the first and second insulating layers, and the source and drain electrodes located on both sides of the organic layer respectively.2. The organic electronic light emitting device of claim 1 , wherein the organic layer comprising:a first organic layer formed on the upper surface of the first insulating layer; anda second organic layer formed on an upper surface of the first organic layer.3. The organic electronic light emitting device of claim 2 , wherein the source electrode is located at an upper surface of the first insulation layer claim 2 , an upper surface of the first organic layer claim 2 , an lower surface of the second organic ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide has an extracellular signaling activity.128. The therapeutic composition of claim 126 , wherein the AARS polypeptide consists of an amino acid sequence set forth in any of Table(s) 1-9 or differs from an amino acid sequence set forth in any of Table(s) 1-9 by substitution claim 126 , deletion claim 126 , and/or addition of about 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide that is at least 80% claim 126 , 85% claim 126 , 90% claim 126 , 95% claim 126 , 98% claim 126 , or 100% identical to an amino acid sequence set forth in any of Table(s) 1-9.132. The isolated AARS polypeptide of claim 131 , wherein the AARS polypeptide is fused to a heterologous polypeptide.133. The isolated AARS polypeptide of claim 131 , further comprising an element selected from the group ...

OPTICAL QUANTIFICATION OF INTERFACIAL CHARGE STATES

Methods of generating second harmonic generation (SHG) signals from interfaces formed with, or formed over, a noncentrosymmetric material, e.g., α-quartz, are provided. The methods make use of the noncentrosymmetric material as an internal phase reference for the determination of a variety of interfacial electrostatic parameters, including interfacial potential, interfacial charge density, and the sign of the interfacial charge (i.e., net positive or net negative). 1. An apparatus for probing an interface via second harmonic generation (SHG) spectroscopy , the apparatus comprising:(a) a sample cell comprising a noncentrosymmetric material having a selected orientation angle with respect to a reference axis;(b) optics configured to illuminate an interface formed between the noncentrosymmetric material and a different material, or formed between two different materials and disposed over the noncentrosymmetric material, with light having a frequency ω under conditions to generate a second harmonic generation (SHG) signal having frequency 2ω;(c) a detector configured to detect the SHG signal, the SHG signal comprising a bulk second harmonic signal from the noncentrosymmetric material and an interfacial second harmonic signal from the interface; and illuminate the interface to generate the SHG signal; and', 'detect the SHG signal., '(d) a device comprising a processor and a computer-readable medium operably coupled to the processor, the computer-readable medium having computer-readable instructions stored thereon that, when executed by the processor, cause the apparatus to'}2. The apparatus of claim 1 , the computer-readable medium further having computer-readable instructions stored thereon that claim 1 , when executed by the processor claim 1 , cause the device to associate the detected SHG signal with an interfacial charge at the interface.3. The apparatus of claim 2 , wherein associating the detected SHG signal with the interfacial charge is carried out by comparing ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

AUTOMATIC POSITIONING SYSTEM AND METHOD OF USING SAME

The present disclosure provides an automatic positioning system that is in a mobile device. The mobile device communicates with a vehicle. The system includes a first detection module, a second detection module and a positioning module. The first detection module detects the mobile device is in a moving state or a static state in real-time. The second detection module detects the vehicle is in a moving state or a static state in real-time. The positioning module acquires the location of the mobile device and records the acquired location as a position where the vehicle is parked in the mobile device, when the vehicle changes from the moving state to the static state, the mobile device changes from the static state to the moving state. 1. An automatic positioning system in a mobile device , the mobile device communicating with a vehicle via a wireless network , the automatic positioning system comprising:a first detection module that detects a motion state of the mobile device to determine if the mobile device is in a moving state or a static state in real-time;a second detection module that detects a motion state of the vehicle to determine if the vehicle is in a moving state or a static state in real-time; anda positioning module that acquires the location of the mobile device and records the acquired location as a position of the vehicle in the mobile device, when the vehicle changes from a moving state to a static state, the mobile device changes from a static state to a moving state.2. The automatic positioning system according to claim 1 , further comprising:a navigation module that acquires a current location of the mobile device as a starting point, reads the recorded position as an ending point, and calculates a path from the starting point to the ending point to guide the user back to the vehicle.3. The automatic positioning system according to claim 1 , wherein the mobile device further comprises a first detection unit claim 1 , the first detection module ...

Total Flavonoid Extract From Gynura Formosana Kitam., Preparation Method Thereof, And Use Of Same In Preparing Drug Or Health Product Related To Alcoholic Fatty Liver Disease

A total flavonoid extract from Kitam., comprising, in weight percent, 80-85% of rutin. A method for preparing the total flavonoid extract from Kitam. comprises solvent extraction, complex enzymatic hydrolysis, and separation and purification by a macroporous resin. The total flavonoid extract from Kitam. is used to prepare a drug or health product related to alcoholic fatty liver disease. 1Gynura formosana. A total flavonoid extract from Kitam. , comprising , in weight percent , 80-85% of rutin.2Gynura formosana. A preparation method of a total flavonoid extract from Kitam. , the total flavonoid extract comprising , in weight percent , 80-85% of rutin , the method comprising the steps of:{'i': 'Gynura formosana', '(1) Extraction: extracting Kitam., with an extraction solvent to obtain an extraction solution, and adjusting the extraction solution to a pH of 4-8 to obtain a reaction solution;'}(2) Enzymolysis: adding a complex enzyme into the reaction solution to carry out enzymolysis through a forced circular reaction at a temperature of 30° C. to 50° C. for 1 to 4 hours, then carrying out suction filtration, and collecting a filtrate;(3) Extraction and Concentration: extracting the filtrate by using a macroporous resin A to obtain an extracted solution, and concentrating the extracted solution to obtain a concentrated solution;(4) Separation and Purification: centrifuging the concentrated solution, collecting a supernatant and carrying out elution by using a macroporous resin B, measuring absorbance at a wavelength of 510 nm, collecting eluate, concentrating and drying the eluate to obtain an extract.3Gynura formosana. The preparation method of claim 2 , wherein the complex enzyme used in the enzymolysis step consists of papain claim 2 , cellulase and pectinase; and wherein a weight ratio of the complex enzyme to the Kitam. is 1:5 to 1:3.4. The preparation method of claim 2 , wherein a weight ratio of papain to cellulase to pectinase in the complex enzyme is (0.5-1. ...

TOTAL FLAVONOID EXTRACT FROM GYNURA FORMOSANA KITAM., PREPARATION METHOD THEREOF, AND USE OF SAME IN TREATING NON-ALCOHOLIC FATTY LIVER DISEASE

A total flavonoid extract from Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease. 1Gynura formosana. A total flavonoid extract from Kitam. , comprising , in weight percent , 80-85% of rutin.2Gynura formosana. A preparation method of a total flavonoid extract from Kitam. , the total flavonoid extract comprising , in weight percent , 80-85% of rutin , the method comprising the steps of:{'i': 'Gynura formosana', '(1) Extraction: extracting Kitam. with an extraction solvent to obtain an extraction solution, and adjusting the extraction solution to a pH of 4-8 to obtain a reaction solution;'}(2) Enzymolysis: adding a complex enzyme into the reaction solution to carry out enzymolysis through a forced circular reaction at a temperature of 30° C. to 50° C. for 1 to 4 hours, then carrying out suction filtration, and collecting a filtrate;(3) Extraction and Concentration: extracting the filtrate by using a macroporous resin A to obtain an extracted solution, and concentrating the extracted solution to obtain a concentrated solution;(4) Separation and Purification: centrifuging the concentrated solution, collecting a supernatant and carrying out elution by using a macroporous resin B, measuring absorbance at a wavelength of 510 nm, collecting eluate, concentrating and drying the eluate to obtain an extract.3Gynura formosana. The preparation method of claim 2 , wherein the complex enzyme used in the enzymolysis step consists of papain claim 2 , cellulase and pectinase; and wherein a weight ratio of the complex enzyme to the Kitam. is 1:5 to 1:3.4. The preparation method of claim 2 , wherein a weight ratio of papain to cellulase to pectinase in the complex enzyme is (0.5-1.5):(2 ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

Total Flavonoids Extract of Gynura Formosana Kitam., Preparation Method Therefor and Use Thereof for Treating Hyperuricemia

Disclosed is a total flavonoids extract of ., containing 80%-85% of rutin by weight percent content. The results of pharmacological experiments show that the extract can lower the activity of xanthine oxidase in the liver of a hyperuricemia model mouse and reduce the synthesis of uric acid to a certain degree and has a certain uric acid-lowering effect, and can be used as a potential drug for treating hyperuricemia or gout. The method for preparing the total flavonoids extract of . comprises: after an extraction step, selecting a complex enzyme composed of enzymes with a specific composition and a specific ratio for enzymolosis, and further carrying out the step of extracting and concentrating with macroporous resin and isolating and purifying with macroporous resin, so that the HPLC purity of rutin in the resulting total flavonoids extract of . reaches 80%-85%. 1Gynura formosana KitamGynura formosana Kitam. A method for treating hyperuricemia or gout , comprising the step of administrating a total flavonoid extract from . to a subject in need , wherein the total flavonoid extract from . , comprises , in weight percent , 80-85% of rutin.2Gynura formosana Kitam. The method of claim 1 , wherein the total flavonoid extract from . is prepared by the steps of:{'i': 'Gynura formosana Kitam', '(1) Extraction: extracting . with an extraction solvent to obtain an extraction solution, and adjusting the extraction solution to a pH of 4-8 to obtain a reaction solution;'}(2) Enzymolysis: adding a complex enzyme into the reaction solution to carry out enzymolysis through a forced circular reaction at a temperature of 30° C. to 50° C. for 1 to 4 hours, then carrying out suction filtration, and collecting a filtrate;(3) Extraction and Concentration: extracting the filtrate by using a macroporous resin A to obtain an extracted solution, and concentrating the extracted solution to obtain a concentrated solution;(4) Separation and Purification: centrifuging the concentrated solution, ...

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

SEMICONDUCTOR DEVICE AND METHOD OF MANUFACTURING SEMICOUNDUCTOR DEVICE

A forward termination structure that surrounds an active region is provided between the active region and a p isolation region. A reverse termination structure that surrounds the forward termination structure is provided between the forward termination structure and the p isolation region. The forward termination structure is formed of a plurality of first field limited rings (“FLR”) and a first filed plat (“FP”) conductively connected to the first FLR. The reverse termination structure is formed of a plurality of second FLR and second FP conductively connected to the second FLR. In the reverse termination structure, a second n-type region which is in contact with the p isolation region and which includes at least one of the second FLRs is provided on a surface layer of the front surface of an n semiconductor substrate. 2. The semiconductor device according to claim 1 , whereinthe first conductivity-type semiconductor region includes at least the one second conductivity-type semiconductor region.3. The semiconductor device according to claim 1 , further comprising:a channel stopper region provided in the surface layer of the front surface of the first conductivity-type semiconductor substrate at a boundary between the first edge termination region and the second edge termination region so as to stop a depletion layer which expands from the side of the active region during application of a forward voltage; anda first metal film being in contact with the channel stopper region.4. The semiconductor device according to claim 1 , further comprising:a channel stopper region provided in the surface layer of the front surface of the first conductivity-type semiconductor substrate at a boundary between the first edge termination region and the second edge termination region so as to stop a depletion layer which expands from the side of the second conductivity-type isolation region during application of a reverse voltage; anda first metal film being in contact with the ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3 , or Table(s) 4-6 , and Table(s) 7-9 , wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.128. The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.129. The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.130. The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.131. The therapeutic composition of claim 126 , wherein the composition is a sterile claim 126 , freeze-dried powder.132. The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.133. The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.134. The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous claim 126 , intramuscular claim 126 , subcutaneous claim 126 , or intraperitoneal administration.135. The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.136. The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.137. A method of modulating a ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1139-. (canceled)140. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.141. The therapeutic composition of claim 140 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.142. The therapeutic composition of claim 140 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 140 , or Table(s) 4-6 claim 140 , or Table(s) 7-9 claim 140 , by substitution claim 140 , deletion claim 140 , and/or addition of about 0 claim 140 , 1 claim 140 , 2 claim 140 , 3 claim 140 , 4 claim 140 , 5 claim 140 , 6 claim 140 , 7 claim 140 , 8 claim 140 , 9 claim 140 , 10 claim 140 , or 11 amino acids claim 140 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.143. The therapeutic composition of claim 140 , wherein the AARS polypeptide is fused to a heterologous polypeptide.144. The therapeutic composition of claim 140 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.145. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 140 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. 1125-. (canceled)126. A therapeutic composition , comprising an isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% , 85% , 90% , 95% , 98% , or 100% identical to a sequence in any of Table(s) 1-3 , or Table(s) 4-6 , or Table(s) 7-9 , wherein the polypeptide has a solubility of at least about 5 mg/mL , and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.127. The therapeutic composition of claim 126 , wherein the polypeptide specifically binds to a binding partner to exert a physiological effect.128. The therapeutic composition of claim 126 , wherein said polypeptide differs from an amino acid sequence set forth in any of Table(s) 1-3 claim 126 , or Table(s) 4-6 claim 126 , or Table(s) 7-9 claim 126 , by substitution claim 126 , deletion claim 126 , and/or addition of about 0 claim 126 , 1 claim 126 , 2 claim 126 , 3 claim 126 , 4 claim 126 , 5 claim 126 , 6 claim 126 , 7 claim 126 , 8 claim 126 , 9 claim 126 , 10 claim 126 , or 11 amino acids claim 126 , and wherein the altered polypeptide substantially retains a non-canonical activity of the unaltered protein.129. The therapeutic composition of claim 126 , wherein the AARS polypeptide is fused to a heterologous polypeptide.130. The therapeutic composition of claim 126 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.131. An isolated aminoacyl-tRNA synthetase (AARS) polypeptide of about 100 to about 750 amino acids in length and comprising an amino acid sequence that is at least 80% claim 126 , 85% ...

RB-IGBT

An RB-IGBT is provided that has a new emitter trench structure with improved breakdown voltage achieved by improving the electrical field distribution of the drift region. The RB-IGBT includes an isolation region having a first conductivity type on a side surface of a semiconductor substrate. The semiconductor substrate includes a drift region having a second conductivity type; a collector region having the first conductivity type and provided farther downward than the drift region; and an emitter trench portion provided extending to the drift region in a thickness direction from a front surface to a back surface of the semiconductor substrate. The emitter trench portion includes a trench electrode electrically connected to an emitter electrode provided above the semiconductor substrate; an upper trench insulating film directly contacting a bottom portion and side portions of the trench electrode; and a lower trench insulating film provided below the upper trench insulating film. 1. An RB-IGBT including an isolation region having a first conductivity type on a side surface of a semiconductor substrate , whereinthe semiconductor substrate includes:a drift region having a second conductivity type;a collector region having the first conductivity type and provided farther downward than the drift region; andan emitter trench portion provided extending to the drift region in a thickness direction that is from a front surface of the semiconductor substrate to a back surface of the semiconductor substrate, andthe emitter trench portion includes:a trench electrode that is electrically connected to an emitter electrode provided above the semiconductor substrate;an upper trench insulating film that directly contacts a bottom portion and side portions of the trench electrode; anda lower trench insulating film provided below the upper trench insulating film.2. The RB-IGBT according to claim 1 , whereinthe lower trench insulating film has a dielectric constant that is lower than ...